Can You Test for Spike Proteins and Immunity?

Tests for both spike protein and various branches of immune response to SARS-CoV-2 do exist, ranging from ultrasensitive blood assays that detect picogram-level quantities of spike protein to antibody panels and T-cell tests that measure different facets of immunity. But what any given test can tell you about your actual protection from illness is more limited than most people assume, and major medical guidelines currently recommend against routine serologic testing for people who have been vaccinated or previously infected. The gap between what is technically measurable and what is clinically useful is worth understanding.

Detecting the Spike Protein Itself

If the question is whether spike protein can be found floating in the blood after infection or vaccination, the answer is yes, though it takes specialized equipment. Researchers have developed ultrasensitive digital ELISA methods that can pick up spike protein at concentrations as low as roughly 20 femtograms per milliliter, which is far below what a standard hospital lab test would catch.¹ These single-molecule array (Simoa) assays were used in a study at Brigham and Women’s Hospital to track what happens after mRNA vaccination: spike protein subunits appeared briefly in the blood, the immune system mounted its response, and then the protein was cleared to below detectable levels.²

Mass spectrometry offers another detection route. Researchers have used isotope dilution mass spectrometry to quantify spike protein produced by cells transfected with mRNA vaccines in laboratory settings, achieving precise measurements across multiple peptide fragments simultaneously.³ Separate work validated a mass spectrometry approach for detecting SARS-CoV-2 nucleocapsid protein directly from nasopharyngeal swabs, using machine learning to classify positive samples.⁴ These tools are powerful but largely confined to research labs. You won’t find a spike protein blood test at your local urgent care clinic.

How Long Does Spike Protein Stick Around

After vaccination, circulating spike protein appears within days, peaks around two weeks, and is generally cleared as the immune system ramps up. One study found that exosomes carrying spike protein on their surface appeared by day 14 after the first mRNA vaccine dose, followed by antibodies about 14 days after the second dose.⁵ Those spike-carrying exosomes aren’t a sign of something going wrong; they appear to play a role in triggering the immune response that vaccination is designed to produce.

After natural COVID-19 infection, the timeline can be longer. Research on human tissue samples has found spike protein accumulating in the skull-meninges-brain axis of COVID-19 patients, persisting well after the virus itself is no longer replicating.⁶ And one review of clinical data reported that modified mRNA from vaccines can persist up to about a month after injection, with recombinant spike protein potentially detectable in blood for over six months in some cases.⁷ Whether trace-level persistence of spike protein has clinical consequences is an active area of investigation, but the point here is that detecting it is technically feasible with the right assay.

Antibody Tests and What They Actually Measure

When most people ask about “testing for immunity,” they mean antibody tests. These are far more widely available than spike protein assays. But there are important distinctions between types of antibody tests, and picking the wrong one can give you a misleading picture.

The most common commercial tests look for antibodies against the spike protein (anti-S or anti-RBD antibodies) or antibodies against the nucleocapsid protein (anti-N antibodies). Vaccines based on spike protein, which includes all the major mRNA and viral vector vaccines, generate anti-spike antibodies. Natural infection generates antibodies against both spike and nucleocapsid proteins. This difference is the basis for distinguishing vaccine-induced immunity from infection-induced immunity: if you have anti-nucleocapsid antibodies, you’ve been infected, regardless of your vaccination status.⁸

Large-scale validation of nucleocapsid antibody assays has shown strong sensitivity for detecting past infections. One evaluation using blood donor samples found that the assay correctly identified first infections in about 98% of unvaccinated donors and about 96% of vaccinated donors.⁹ That slight sensitivity drop in vaccinated people is worth noting: vaccination can subtly change how the immune system responds to a subsequent infection, sometimes blunting the anti-nucleocapsid response enough to make detection trickier.

Newer multiplexed point-of-care tests aim to measure neutralizing antibodies, anti-nucleocapsid, and anti-spike levels all at once, which gives a richer snapshot. One such test found that roughly a third of the patients assessed had anti-nucleocapsid activity alongside their anti-spike antibodies, revealing that their immunity came from a combination of vaccination and prior infection rather than vaccination alone.¹⁰ That kind of detail matters for people trying to understand their own immune history.

Neutralizing Antibodies and What They Say About Protection

Not all antibodies are created equal. Some bind to the virus without stopping it from entering cells. The ones that block viral entry, called neutralizing antibodies, are the best-studied correlate of protection against symptomatic COVID-19. The traditional way to measure them is a plaque reduction neutralization test, which requires live virus and a high-security lab.¹¹ Because that’s impractical for routine use, surrogate neutralization tests have been developed. One well-validated version works by checking whether a person’s antibodies can block the spike protein from binding to the ACE2 receptor in a test tube, achieving over 99% specificity and 95–100% sensitivity without needing a biosafety level 3 facility.¹²

What makes neutralizing antibody levels meaningful is their relationship to actual protection. A widely cited modeling study found a strong correlation between a vaccine’s average neutralization level measured early after dosing and its protective efficacy reported in phase 3 trials. The estimated neutralization level needed for 50% protection was about 20% of the average level seen in people recovering from natural infection.¹³ Multiple studies converge on a consistent relationship between neutralizing antibody levels and protection, even across different vaccines and study designs.¹⁴

With Omicron variants, however, the picture got messier. One study found that simple spike-binding antibody titers were not associated with protection from BA.1 or BA.2 infection on their own, though both neutralizing and spike-binding titers were associated with protection from symptomatic disease across waves.¹⁵ In other words, a high antibody number on a lab report might protect you from getting severely sick but won’t necessarily prevent infection, especially with newer variants that have mutated their spike protein away from what the immune system was trained to recognize.

T-Cell Tests and the Other Half of Immunity

Antibodies get all the attention, but T cells are at least as important for long-term protection. They don’t prevent infection in the way neutralizing antibodies can, but they kill infected cells and coordinate the broader immune response, which is critical for preventing severe disease. And unlike antibodies, which can wane substantially within months, T-cell responses tend to be more durable.

Tests for SARS-CoV-2-specific T cells exist, mainly in the form of interferon-gamma release assays (IGRAs). These work by exposing a blood sample to spike protein peptides and measuring whether T cells respond by releasing interferon-gamma, a signaling molecule. Two commercially available tests, QuantiFERON SARS-CoV-2 and T-SPOT.COVID, use this approach. In a head-to-head comparison, QuantiFERON detected spike-specific T cells in about 35% of participants and T-SPOT.COVID in about 22%, while a custom ELISpot assay using Omicron-specific peptides picked them up in about 48%.¹⁶ The T-SPOT.COVID test specifically measures responses to both spike and nucleocapsid peptides, which means it can pick up T-cell immunity from infection even in people who were also vaccinated.¹⁷

The wide variation in detection rates across these assays hints at the core problem: T-cell testing is harder to standardize than antibody testing. Results depend heavily on which peptides the test uses, how the blood sample is handled, and the specific cutoff values applied. A negative result on one T-cell test doesn’t necessarily mean you lack T-cell immunity; it may mean the test’s peptide mix doesn’t match the variant your immune system learned from, or that your T cells respond to parts of the virus the test doesn’t cover.

Why Antibody Levels Alone Miss the Full Picture

A common concern is that declining antibody levels mean waning protection. Antibody titers do drop in the months after infection or vaccination, and for some people, neutralizing antibodies fall below detectable levels within about six months. But this doesn’t mean immunity is gone. One study tracked people for six months after infection and found that while about 13% had neutralizing antibody levels that dropped back to baseline, 12 out of 13 still had detectable memory B cells specific to the spike protein’s receptor-binding domain, and those cells were actually increasing over time.¹⁸ Follow-up research confirmed that spike-specific memory B cells persist at high levels for at least 12 months after infection and respond effectively when re-exposed to the antigen.¹⁹

Memory B cells are essentially sleeping factories. When they encounter the virus again, they wake up and start churning out antibodies rapidly, often producing upgraded versions that are more effective than the originals. No widely available commercial test measures memory B cells directly. The research assays that do exist involve sorting individual B cells and testing whether they can produce antibodies, which is labor-intensive and impractical for clinical use. This means the most important layer of long-term immune readiness is essentially invisible to the tests you can actually get.

Mucosal Immunity Is Mostly Unmeasured

The immune response in your nose and throat, where respiratory viruses first land, is a separate arm of defense from what circulates in the blood. IgA antibodies in saliva and nasal secretions can neutralize the virus before it establishes a foothold. After mRNA vaccination, most people produce some anti-spike IgA in saliva, but this fades quickly. One study found that only about 30% of participants remained positive for salivary IgA after the second vaccine dose.²⁰ Participants who later had breakthrough infections tended to have lower levels of vaccine-induced IgA compared to those who didn’t get infected, even though their IgG levels were similar.

There’s also evidence that robust mucosal IgA matters for recovery speed. A study measuring secretory IgA in oral fluid found that people with high levels of anti-spike secretory IgA after infection cleared the virus about two weeks faster and recovered from symptoms about 9 to 10 days sooner than those with lower levels.²¹ Interestingly, higher IgG levels in saliva were associated with slower clearance, suggesting that the blood-derived antibody response and the mucosal response play different and sometimes opposing roles. Saliva-based IgA testing is currently a research tool, not something your doctor would order, but it highlights a real gap in what standard blood tests capture.

Cross-Reactivity From Common Cold Coronaviruses

One subtle issue with antibody testing is that your immune system doesn’t start from scratch with SARS-CoV-2. Most adults have been infected multiple times by seasonal coronaviruses like OC43, HKU1, NL63, and 229E, which cause ordinary colds. These viruses share structural features with SARS-CoV-2, especially in the S2 region of their spike proteins. Antibodies from past cold coronavirus infections can cross-react with SARS-CoV-2 antigens in testing, and conversely, COVID-19 can boost antibodies against seasonal coronaviruses through a phenomenon called backboosting.²²

A study of recovered COVID-19 patients found antibody repertoires with binding patterns that extended beyond SARS-CoV-2 to other human coronaviruses and even animal coronaviruses, mediated by shared protein motifs.²³ At the B-cell level, a substantial proportion of SARS-CoV-2-reactive clones also bind to seasonal coronavirus spike proteins.²⁴ For the average person, this cross-reactivity is mostly a curiosity. But for diagnostic purposes, it means some antibody signal in a SARS-CoV-2 test might actually come from past encounters with completely different viruses. Well-designed tests account for this by using protein targets specific enough to minimize false positives, but cheaper or older assays can be tripped up.

Why Testing Matters More for Immunosuppressed People

For most healthy adults, the practical value of knowing an exact antibody number is limited, since multiple overlapping layers of immunity make interpretation ambiguous. For immunosuppressed people, the stakes are different. Individuals with severe immunosuppression from blood cancers or organ transplants can have dramatically impaired immune responses. One study found that these patients took a median of 72 days to clear nasal viral RNA, compared to much shorter clearance times in healthy individuals. Both groups with severe immunosuppression, whether from hematologic conditions or autoimmune diseases, showed diminished antibody responses. But only the hematologic/transplant group also had reduced T-cell responses, suggesting their immune deficit was broader.²⁵

For these patients, antibody testing after vaccination can genuinely inform clinical decisions, such as whether to administer additional vaccine doses or prescribe prophylactic monoclonal antibodies. This is one of the few settings where measuring antibody response has a clear practical benefit, and clinical guidelines tend to carve out exceptions for immunocompromised people even while recommending against routine serologic testing in the general population.

Why Your Doctor Probably Won’t Order These Tests

Despite all the tests that exist, the Infectious Diseases Society of America recommends against routine serologic testing in individuals who have been previously infected or vaccinated, citing no demonstrated benefit to improving patient outcomes.²⁶ That recommendation sounds counterintuitive if you’ve just read about all the ways immunity can be measured. The reasoning comes down to several practical issues.

First, there is no universally accepted antibody threshold that guarantees protection. The correlation between neutralizing antibodies and efficacy exists at the population level, across large groups in clinical trials, but translating a single person’s antibody number into a personal probability of staying healthy isn’t possible with current knowledge. Second, antibody levels are a moving target. A blood draw captures a snapshot that might look very different three months later, yet the person’s actual protection may not have changed meaningfully because memory B cells and T cells compensate for declining circulating antibodies. Third, different tests use different units, different protein targets, and different cutoff values, making it difficult to compare results across labs or over time.

The combination of these factors means that a person who gets a test showing “low” antibodies might panic unnecessarily, while someone with “high” antibodies might develop a false sense of invulnerability to newer variants. For most people, the public health recommendation remains more straightforward: stay up to date on vaccination regardless of what any test says about your current antibody level.

Rapid Antigen Tests and Their Limitations

The rapid tests most people have used at home are lateral flow assays that detect SARS-CoV-2 proteins, typically nucleocapsid rather than spike, from a nasal swab. These serve a different purpose entirely: they tell you whether you’re currently infected and shedding detectable levels of virus, not whether you have immunity. Their main limitation has always been sensitivity. Lateral flow assays are fast, cheap, and can be used without trained personnel, but they miss infections at lower viral loads, particularly in the early and late stages of illness.²⁷ A negative rapid test does not rule out infection, and it tells you nothing about your immune status.

Extracellular vesicles add another layer of complexity worth knowing about. Research has shown that spike protein can be incorporated into small membrane-bound particles released by cells, and these spike-carrying vesicles can act as decoys that soak up neutralizing antibodies, reducing their effectiveness.²⁸ This is a mechanism that plays out inside the body during active infection and doesn’t directly affect how a test in a lab works, but it does illustrate why a simple antibody count doesn’t always translate to a proportional level of real-world protection. Biology has more moving parts than any single assay can capture.